Caribou Biosciences (CRBU) Free Cash Flow (2020 - 2026)
Caribou Biosciences (CRBU) reported Free Cash Flow of -$27.0 million for Q1 2026, up 26.71% year-over-year from -$21.3 million in Q1 2025, and down 30.97% on a QoQ basis from -$20.6 million in Q4 2025.
Caribou Biosciences (CRBU) has 7 years of Free Cash Flow data on file, last reported at -$27.0 million in Q1 2026.
- Quarterly Free Cash Flow rose 26.71% year-over-year to -$27.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$102.5 million (up 25.57% YoY) and the FY2025 annual result came in at -$112.4 million, up 19.14% from the prior year.
- Free Cash Flow retreated to -$27.0 million in Q1 2026 per CRBU's latest filing, from -$20.6 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$18.1 million in Q2 2023 and bottomed at -$38.1 million in Q1 2024.
- The 5-year median for Free Cash Flow is -$26.4 million (2022), against an average of -$27.3 million.
- The widest annual swing landed in 2022, when Free Cash Flow sank 211.65%; it then soared 42.5% in 2025.
- Tracing CRBU's Free Cash Flow over 5 years: stood at -$21.6 million in 2022, then increased by 0.25% to -$21.5 million in 2023, then plunged by 66.63% to -$35.9 million in 2024, then soared by 42.5% to -$20.6 million in 2025, then plunged by 30.97% to -$27.0 million in 2026.
- Per Business Quant, the three latest CRBU Free Cash Flow figures stand at -$27.0 million (Q1 2026), -$20.6 million (Q4 2025), and -$25.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | -27.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.00 Mn |
| Mar 31, 2026 | -27.00 Mn |
| Dec 31, 2025 | -20.62 Mn |
| Dec 31, 2025 | -20.62 Mn |
| Sep 30, 2025 | -25.30 Mn |
| Sep 30, 2025 | -25.30 Mn |
| Jun 30, 2025 | -29.60 Mn |
| Jun 30, 2025 | -29.60 Mn |
| Mar 31, 2025 | -36.84 Mn |
| Mar 31, 2025 | -36.84 Mn |
| Dec 31, 2024 | -35.85 Mn |
| Dec 31, 2024 | -35.85 Mn |
| Sep 30, 2024 | -32.86 Mn |
| Sep 30, 2024 | -32.86 Mn |
| Jun 30, 2024 | -32.19 Mn |
| Jun 30, 2024 | -32.19 Mn |
| Mar 31, 2024 | -38.05 Mn |
| Mar 31, 2024 | -38.05 Mn |
| Dec 31, 2023 | -21.52 Mn |
| Dec 31, 2023 | -21.52 Mn |
| Sep 30, 2023 | -24.76 Mn |
| Sep 30, 2023 | -24.76 Mn |
| Jun 30, 2023 | -18.06 Mn |
| Jun 30, 2023 | -18.06 Mn |
| Mar 31, 2023 | -29.65 Mn |
| Mar 31, 2023 | -29.65 Mn |
| Dec 31, 2022 | -21.57 Mn |
| Dec 31, 2022 | -21.57 Mn |
| Sep 30, 2022 | -26.37 Mn |
| Sep 30, 2022 | -26.37 Mn |
| Jun 30, 2022 | -21.60 Mn |
| Jun 30, 2022 | -21.60 Mn |
| Mar 31, 2022 | -22.65 Mn |
| Mar 31, 2022 | -22.65 Mn |
| Dec 31, 2021 | -22.07 Mn |
| Dec 31, 2021 | -22.07 Mn |
| Sep 30, 2021 | -15.90 Mn |
| Sep 30, 2021 | -15.90 Mn |
| Jun 30, 2021 | -16.96 Mn |
| Jun 30, 2021 | -16.96 Mn |
| Mar 31, 2021 | 20.29 Mn |
| Mar 31, 2021 | 20.29 Mn |
| Dec 31, 2020 | -8.10 Mn |
| Dec 31, 2020 | -8.10 Mn |
| Sep 30, 2020 | -8.71 Mn |
| Sep 30, 2020 | -8.71 Mn |